A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Active, not recruiting · Phase 3 · NCT06972472
Conditions: Obesity, Overweight, Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $40,397
- U.S. investigators named
- 30
- Sites paid
- 23
- Planned or actual enrollment
- 600
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2025-05-19; completion 2027-08
- Results posted
- Not yet
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
From ClinicalTrials.gov, last updated 2026-04-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $40,397 in research payments for this study in 2025 (34 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jalal M. Abbas, M.D. Internal Medicine · Sun City West, AZ
- Thili N. Kulatilake, M.D. Family Medicine · Tucson, AZ
- Irving K. Loh, MD Cardiology · Thousand Oaks, CA
- Yshay Shlesinger, M.D. Internal Medicine · San Ramon, CA
- Malisa Agard, M.D. Internal Medicine · Orlando, FL
- Jose F. Cardona, M.D. General Practice · Miami, FL
- Jose M. Mandry, M.D. Endocrinology & Diabetes · Ocoee, FL
- Shital R. Mehta, D.O. Internal Medicine · Wesley Chapel, FL
- Rodolfo A. Perez, M.D. Specialist · Hialeah, FL
- Christopher J. Oldfield, M.D. Family Medicine · Savannah, GA
- Marie L. Walton, MD, MPH Research Clinic/Center · Riverdale, GA
- Bram Wieskopf, MD Internal Medicine · Woodstock, GA
- David Butuk, MD Family Medicine · Meridian, ID
- Son V. Nguyen, M.D. Gastroenterology · New Iberia, LA
- Husna Baksh, M.D. Internal Medicine · Silver Spring, MD
- Helena W. Rodbard, M.D. Endocrinology & Diabetes · Rockville, MD
- Jeffrey A. Potts, MD Internal Medicine · Bay City, MI
- Aubrey M. Remmers, M.D. Family Medicine · Missoula, MT
- Christina C. Kennelly, M.D. Internal Medicine · Charlotte, NC
- Klara Klein, MD/PHD Endocrinology & Diabetes · Chapel Hill, NC
- Daniel C. Uba, MD/INTERNAL MEDICINE Internal Medicine · Fayetteville, NC
- Sangeeta S. Wagner, DO Family Medicine · Sparks, NV
- Patricia S. Hopson, DO Endocrinology & Diabetes · Corvallis, OR
- Marcy J. Goisse, MD Family Medicine · Smithfield, PA
- Elham S. Ghorbani, MD General Practice · Dorado, PR
- Paola Mansilla-letelier, M.D Endocrinology & Diabetes · Guaynabo, PR
- Donald F. Gardner, MD Specialist · Houston, TX
- Alejandro Gonzalez Campos, M.D Endocrinology & Diabetes · Edinburg, TX
- Dan Lender, MD Endocrinology & Diabetes · Rockwall, TX
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Novak Clinical Research $6,339
- $4,997
- Javara $4,159
- Texas Valley Clinical Research LLC $3,499
- Care Access Research LLC $3,247
- West Orange Endocrinology PA $2,343
- Encore Medical Research, LLC $2,278
- Indago Research & Health Center Inc $1,720
- Puerto Rico Health Institute LLC $1,280
- Velocity Clinical Research Inc $1,211
- Boeson Research LLC $1,041
- Biopharma Informatic Inc $982
- Intend Research LLC $927
- Yshay Shlesinger MD $910
- Solaris Clinical Research LLC $869
- University of North Carolina at Chapel Hill $856
- Frontier Clinical Research LLC $720
- Consano Clinical Research LLC $638
- Clinical Research Institute Inc $466
- Great Lakes Research Group Inc $466
- Conquest Research LLC $466
- Corvallis Clinic PC $438
- North Georgia Clinical Research $276
- Helena W Rodbard, MD, PA $269
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.